Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers‡.
Loading...
Embargo End Date
ICR Authors
Authors
Khalique, S
Nash, S
Natrajan, R
Nash, S
Natrajan, R
Document Type
Journal Article
Date
2022-06-29
Date Accepted
2022-05-30
Abstract
The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to hold prognostic significance in a range of solid malignancies, yet in endometriosis-related ovarian carcinomas there has been a lack of clarity of its prognostic role. Moreover, the relationship between ARID1A status and immune infiltrate is also poorly understood. In a recent issue of The Journal of Pathology, a large comprehensive study by Heinze, Nazeran et al addressed these areas by reviewing 1,623 endometriosis-associated ovarian carcinomas and correlating ARID1A status using standardised immunohistochemistry to infer mutation status, with comprehensive clinicopathological features, mismatch repair status and CD8+ tumour infiltrating lymphocytes. The study definitively showed that ARID1A status does not provide any independent prognostic value in endometriosis-associated ovarian carcinomas. ARID1A loss was, however, shown to be associated with mismatch repair deficiency and increased CD8+ tumour infiltrating lymphocytes in endometrioid ovarian carcinoma, which may be relevant for future studies. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Citation
Journal of Pathology, 2022, 258 (1), pp. 1 - 3
Source Title
Journal of Pathology
Publisher
WILEY
ISSN
0022-3417
eISSN
1096-9896
1096-9896
1096-9896
Collections
Research Team
Functional Genomics